GlassScriptPhysician profile
Scott A Mazurek
NPI 1407272081
$831.43
in general payments reported to CMS, 2019-2025
10 companies · $50.13 in 2025
The $50.13 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $25.88 · 2023: $755 · 2025: $50.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $805.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $246.79 | 2023 | Minimed 780g |
| Amryt Pharma Holdings LTD | $147.49 | 2023 | Mycapssa |
| Beta Bionics, INC. | $137.86 | 2023 | Ilet Bionic Pancreas |
| Dexcom, INC. | $125.95 | 2023-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $98.28 | 2023 | Tepezza |
| Ascendis Pharma Endocrinology INC | $18.44 | 2025 | Yorvipath |
| Novo Nordisk INC | $15.68 | 2025 | Ozempic |
| Lilly USA, LLC | $15.06 | 2023 | Baqsimi, Lyumjev, Jardiance |
| Mirum Pharmaceuticals, INC. | $13.55 | 2022 | |
| Xeris Pharmaceuticals, INC. | $12.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Mazurek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.